BDSI BioDelivery Sciences International Inc.

5.75
-0.08  -1%
Previous Close 5.83
Open 5.8
Price To Book 8.33
Market Cap 566,836,087
Shares 98,580,189
Volume 831,172
Short Ratio
Av. Daily Volume 1,630,539
Stock charts supplied by TradingView

NewsSee all news

  1. BDSI Expects Fourth Quarter and 2019 Total Net Sales at the High End of Guidance: Reports Significantly Expanded Insurance Access for Symproic

    2019 Total Company Net Sales Expected at Upper End of $105 to $110 Million More than 25 Million Additional Lives Moved to Preferred Coverage for Symproic® effective January 1, 2020 RALEIGH, N.C., Jan.

  2. BioDelivery Sciences Appoints Kevin Ostrander as Senior Vice President of Business Development

    RALEIGH, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic

  3. BioDelivery Sciences Added to NASDAQ Biotechnology Index

    RALEIGH, N.C., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  4. Emmy® and Tony Award® Winning Actress Kristin Chenoweth Introduces 'This Is Pain' Campaign to Improve the Lives of Those Living with Chronic Pain

    RALEIGH, N.C., Dec. 11, 2019 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  5. BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference

    RALEIGH, N.C., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2b data released December 13, 2016 - primary endpoints not met.
Clonidine gel
Painful diabetic neuropathy (PDN)
Approved June 6, 2014.
BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL
Opioid dependence
Approved October 26, 2015.
BEMA Buprenorphine
Pain

Latest News

  1. BDSI Expects Fourth Quarter and 2019 Total Net Sales at the High End of Guidance: Reports Significantly Expanded Insurance Access for Symproic

    2019 Total Company Net Sales Expected at Upper End of $105 to $110 Million More than 25 Million Additional Lives Moved to Preferred Coverage for Symproic® effective January 1, 2020 RALEIGH, N.C., Jan.

  2. BioDelivery Sciences Appoints Kevin Ostrander as Senior Vice President of Business Development

    RALEIGH, N.C., Jan. 06, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic

  3. BioDelivery Sciences Added to NASDAQ Biotechnology Index

    RALEIGH, N.C., Dec. 19, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  4. Emmy® and Tony Award® Winning Actress Kristin Chenoweth Introduces 'This Is Pain' Campaign to Improve the Lives of Those Living with Chronic Pain

    RALEIGH, N.C., Dec. 11, 2019 /PRNewswire/ -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  5. BioDelivery Sciences to Present at the Piper Jaffray 31st Annual Healthcare Conference

    RALEIGH, N.C., Nov. 27, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  6. BioDelivery Sciences Appoints Dr. Vanila Singh, Former Chief Medical Officer of Health and Human Services, to its Board of Directors

    RALEIGH, N.C., Nov. 25, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  7. BioDelivery Sciences Reports Strong Third Quarter Results, Raises Full Year 2019 and Provides 2020 Net Sales Expectations

    BELBUCA® Net Sales Increased by 115% versus Prior Year to All-time High of $26.5 Million Raises Full Year 2019 Total Company Net Sales Expectations to $105 - $110 Million Provides Full Year 2020 BELBUCA Net Sales

  8. BioDelivery Sciences to Present at the 10th Annual Jefferies Global Healthcare Conference in London

    RALEIGH, N.C., Nov. 07, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  9. BioDelivery Sciences to Report Third Quarter 2019 Financial Results and Host Conference Call on November 12, 2019

    RALEIGH, N.C., Oct. 30, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a specialty pharmaceutical company dedicated to patients living with chronic conditions, today announced its

  10. Calidi Biotherapeutics Announces Appointment of Seasoned Biotech Executive George Ng to Board of Directors

    Calidi Biotherapeutics, Inc. ("Calidi"), a clinical‐stage biotechnology company at the forefront of oncolytic virus-based immunotherapies for cancer, today announced the appointment of seasoned biotech executive, George

  11. Innovate Biopharmaceuticals to Merge with RDD Pharma Creating New Gastroenterology Company Focused on Specialty, Rare and Orphan Diseases

    Deep Clinical-Stage Pipeline Combined With World-Class Leadership TeamOrbiMed Advisors LLC to Lead a Concurrent Capital Raise 9 Meters Biopharma, Inc. Will Be the New Name of the Combined NASDAQ-Listed Public Company

  12. BioDelivery Sciences Announces Significant Additional Insurance Coverage for both BELBUCA® and Symproic®

    Major Pharmacy Benefit Manager (PBM) Improves Access for Both Products to Approximately 14 Million Lives Symproic Will be Listed as Preferred Exclusive and BELBUCA Preferred or Preferred Exclusive RALEIGH, N.C.,

  13. BioDelivery Sciences Announces Participation in Upcoming Investor Conferences

    RALEIGH, N.C., Sept. 17, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  14. BioDelivery Sciences Announces Upcoming Investor Conference Presentations

    RALEIGH, N.C., Aug. 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic

  15. BioDelivery Sciences Announces Five Medical Abstracts Accepted at PAINWeek® 2019 National Conference on Pain Management

    RALEIGH, N.C., Aug. 28, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with chronic conditions, today